Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
| MarketCap | 20.2B |
|---|---|
| PE Ratio | -19.4 |
| PEG Ratio | 1.5 |
| P/B | 9.1 |
| P/S (ttm) | 0.1 |
| Earning Growth (QoQ) | -66% |
| Revenue Growth (QoQ) | |
| Short % | 2% |
| Held by Institutions % | 87% |
| 1 Day Vol Adjusted Return | 0.8 |
| 1 Month Vol Adjusted Return | -1.3 |
| 3 Month Vol Adjusted Return | 1.6 |
| 6 Month Vol Adjusted Return | 17.7 |
| 20 Days SMA Price ZScore | 0.6 |
| 50 Days SMA Price ZScore | -0.5 |
| 12 -26 Days PPO | -0.5 |
| 1 Month Average Short Volume Ratio | 44.3 |
| 1 Day Volume Change ZScore | -0.7 |
| 1 Month Daily Vol | 1.3 |
Stock news
In this article, we will take a look at the 15 undervalued defensive stocks for 2023. You can skip this part and go to 5 Undervalued Defensive Stocks For 2023. Investors flocked to defensive stocks in 2022 amid recession fears and massive losses in the growth stocks space. Defensive stocks are favored by investors during […]
In this article, we will discuss 50 biggest dividend kings and dividend aristocrats. You can skip our detailed analysis of dividend stocks and their returns in the past, and go directly to read Dividend Kings and Aristocrats List: 10 Biggest Stocks. Dividend Aristocrats and Dividend Kings are the companies that have raised their dividend payouts for […]
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have driven up Q1 sales.
Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.
The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.
Cardinal Health's (CAH) second-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.
Here is how Cardinal Health (CAH) and COMPASS Pathways PLC Sponsored ADR (CMPS) have performed compared to their sector so far this year.
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.